プロバイオティクスサプリメントのストレスと不安に対する有効性 (PROfoS)
プロバイオティクスサプリメントのストレスと不安に対する有効性 - 試験期間中の健康な学生を対象とした無作為化プラセボ対照介入研究
This randomized, double-blind, placebo-controlled study evaluates the efficacy and safety of an 8-week probiotic supplementation (Lactobacillus plantarum LP140 and Bifidobacterium breve BB010 in total daily dose 1 × 10¹⁰ CFU or matching placebo) in reducing perceived stress and anxiety, and improvement related psychological parameters in healthy university students during the examination period. The primary outcome is the change in Perceived Stress Scale (PSS-10) score at week 5 and week 8 of interevention compared to placebo. The secondary outcomes are the changes in DASS-21 subscales (Stress, Anxiety, Depression), State-Trait Anxiety Inventory - State version scale (STAI-S), Sense of Coherence Scale (SOC-29), Pittsburgh Sleep Quality Index (PSQI), self-reported gastrointestinal symptoms (Likert scale) and incidence of adverse events during the 8-week lasting interventional study.
調査の概要
詳細な説明
The gut-brain axis enables bidirectional communication between the gastrointestinal tract and the central nervous system. Emerging evidence suggests that selected probiotic strains (psychobiotics) may modulate stress responses and emotional regulation. University examination periods constitute a predictable model of transient psychological stress in otherwise healthy individuals.
This study investigates whether daily supplementation with a probiotic combination of Lactobacillus plantarum LP140 and Bifidobacterium breve BB010 reduces perceived stress and improves related psychological parameters in healthy students exposed to exam-related stress. Two hundred male and female students aged 18-40 years with at least moderate stress and mild anxiety, but without clinical depression, will be enrolled at the Medical University of Lublin, Poland. After providing written informed consent and confirming eligibility criteria, participants will be randomized in a 1:1 ratio to receive either a probiotic formulation containing Lactobacillus plantarum LP140 and Bifidobacterium breve BB010 (total daily dose of 1 × 10¹⁰ colony-forming units) or a matching placebo.
The investigational product and placebo will be identical in appearance and administered orally once daily (two capsules) for 8 weeks. Randomization will be computer-generated, and both participants and investigators will remain blinded to treatment allocation throughout the study. The intervention will begin approximately six weeks before the first scheduled academic examination. Study assessments will be conducted at baseline, at week 5 (approximately one week before the first examination), and at week 8 (±3 days before a subsequent examination). Psychological and functional parameters will be collected using validated self-report instruments administered electronically, with selected assessments performed during on-site visits. Participants will be asked to maintain their usual diet, physical activity, and caffeine intake during the study period. Safety and tolerability will be monitored throughout the intervention, and adverse events will be recorded using an electronic reporting system with daily reminders.
The study is powered to detect clinically meaningful differences between groups in perceived stress levels and will be analyzed using appropriate covariance-based statistical models adjusted for baseline values and relevant covariates. All participant data will be coded to ensure confidentiality and handled in accordance with applicable data protection regulations.
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前:Emilia Majsiak, Professor of University, PhD
- 電話番号:+48667633263
- メール:Emilia.Majsiak@umlub.edu.pl
研究連絡先のバックアップ
- 名前:Bożena Cukrowska, Prof., MD, PhD
- 電話番号:609447892
- メール:bc@nordicbiotic.com
研究場所
-
-
-
Lublin、ポーランド
- 募集
- University of Lublin, Faculty of Health Sciences
-
コンタクト:
- Emilia Majsiak, Prof. PhD
- 電話番号:+48 667633263
- メール:Emilia.Majsiak@umlub.edu.pl
-
主任研究者:
- Emilia Majsiak, Prof., PhD
-
副調査官:
- Renata Markiewicz, PhD
-
副調査官:
- Mariusz Wysokiński, Prof., PhD
-
副調査官:
- Wiesław Fidecki, Prof. PhD
-
副調査官:
- Kinga Zdunek, PhD
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Male or female students aged 18-40 years
- At least moderate stress (DASS-21 Stress score ≥10)
- Mild anxiety (DASS-21 Anxiety score 6-13)
- No clinical depression (DASS-21 Depression score ≤9)
- Willingness to maintain usual diet, physical activity, and intake of caffeinated beverages during the study
- Written informed consent
Exclusion Criteria:
- Irritable bowel syndrome (Rome IV criteria) or any chronic intestinal disease (including celiac disease)
- Known food allergies, immunodeficiency disorders, or immunosuppressive treatment
- Antibiotic use within 4 weeks prior to screening
- Any psychiatric illness within the past 5 years
- Any malignant disease or autoimmune or allergic diseases (e.g., atopic dermatitis, asthma)
- Use of systemic psychotropic medications or steroids; use of topical corticosteroid creams within 4 weeks prior to screening
- Pregnancy, breastfeeding, or plans to become pregnant during the study
- Probiotic or prebiotic consumption or planned dietary changes within 4 weeks prior to screening
- Heavy caffeine consumption (>4 cups of 300 mL coffee per day)
- Drug or alcohol addiction or regular use of recreational drugs
- Smoking more than 10 cigarettes per day
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:防止
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:4倍
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
アクティブコンパレータ:Probiotic
Two capsules containing Lactobacillus plantarum LP140 and Bifidobacterium breve BB010 will be administered orally once daily (total daily dose of 1 × 10¹⁰ colony-forming units) for 8 weeks. |
Lactobacillus plantarum LP140 and Bifidobacterium breve BB010 |
|
プラセボコンパレーター:Placebo
Maltodextrin will be used as a placebo. The placebo capsules will be identical in appearance to the probiotic capsules and will be administered orally once daily (two capsules) for 8 weeks. |
Maltodextrin |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in perceived stress score
時間枠:Change in total perceived stress score from baseline to week 5 and to week 8 (±3 days) compared to placebo
|
Perceived stress will be assessed using the 10-Item Perceived Stress Scale (PSS-10), a validated questionnaire measuring the degree to which situations in one's life are appraised as stressful. The total score ranges from 0 to 40, with higher scores indicating higher perceived stress levels (worse outcome). Changes in the total score from baseline will be analyzed to evaluate the effect of probiotic supplementation. |
Change in total perceived stress score from baseline to week 5 and to week 8 (±3 days) compared to placebo
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in stress, anxiety and depression scores
時間枠:Change in DASS-21 Stress, Anxiety, and Depression subscale scores from baseline to week 5 and week 8 (±3 days) compared to placebo.
|
Stress, anxiety, and depression will be assessed using the Depression Anxiety Stress Scales - 21 Items (DASS-21). The DASS-21 consists of three subscales (Depression, Anxiety, and Stress), each including 7 items. Scores for each subscale range from 0 to 42 after standard score multiplication, with higher scores indicating greater symptom severity (worse outcome). Changes in the Stress, Anxiety, and Depression subscale scores from baseline will be analyzed to evaluate the effect of probiotic supplementation. |
Change in DASS-21 Stress, Anxiety, and Depression subscale scores from baseline to week 5 and week 8 (±3 days) compared to placebo.
|
|
Change in sleep quality score
時間枠:Change in Pittsburgh Sleep Quality Index (PSQI) global score from baseline to week 5 and week 8 (±3 days) compared to placebo.
|
Sleep quality will be assessed using the Pittsburgh Sleep Quality Index (PSQI), a validated questionnaire measuring sleep quality over the previous month. The global PSQI score ranges from 0 to 21, with higher scores indicating poorer sleep quality (worse outcome). Changes in the PSQI global score from baseline will be analyzed to evaluate the effect of probiotic supplementation. |
Change in Pittsburgh Sleep Quality Index (PSQI) global score from baseline to week 5 and week 8 (±3 days) compared to placebo.
|
|
Change in sense of coherence score
時間枠:Change in Sense of Coherence Scale - 29 Items (SOC-29) total score from baseline to week 5 and week 8 (±3 days) compared to placebo.
|
Sense of coherence will be assessed using the Sense of Coherence Scale - 29 Items (SOC-29), a validated questionnaire measuring psychological resilience and the ability to cope with stress. The total score ranges from 29 to 203, with higher scores indicating a stronger sense of coherence (better outcome). Changes in the SOC-29 total score from baseline will be analyzed to evaluate the effect of probiotic supplementation. |
Change in Sense of Coherence Scale - 29 Items (SOC-29) total score from baseline to week 5 and week 8 (±3 days) compared to placebo.
|
|
Change in state anxiety score
時間枠:Change in State-Trait Anxiety Inventory - State version (STAI-S) total score from baseline to week 8 compared to placebo.
|
State anxiety will be assessed using the State-Trait Anxiety Inventory - State version (STAI-S), a validated questionnaire measuring the current level of anxiety. The STAI-S total score ranges from 20 to 80, with higher scores indicating higher levels of anxiety (worse outcome). Changes in the STAI-S total score from baseline will be analyzed to evaluate the effect of probiotic supplementation. |
Change in State-Trait Anxiety Inventory - State version (STAI-S) total score from baseline to week 8 compared to placebo.
|
|
Change in severity of gastro-intestinal symptoms
時間枠:Change from baseline in gastro-intestinal severity score at Week 5 and Week 8 compared to placebo
|
The severitty of gastro-intestinal symptoms will be assessed with the use of 4-point Likert scale (0 - no symptom, 1 - weak, 2 - moderate, 4 - severe). The following symptoms will be assessed: abdominal pain, flatulence, nausea. |
Change from baseline in gastro-intestinal severity score at Week 5 and Week 8 compared to placebo
|
|
Incidence of treatment-emergent adverse events (Safety and Tolerability)
時間枠:From baseline through the 8-week intervention period.
|
Safety and tolerability will be assessed by monitoring the incidence of adverse events throughout the study. Adverse events will be self-reported by participants using an electronic reporting platform, which provides daily reminders for study product intake and allows participants to record any symptoms or adverse events experienced during the study period. |
From baseline through the 8-week intervention period.
|
協力者と研究者
スポンサー
捜査官
- 主任研究者:Emilia Majsiak, Prof. PhD、Medical University of Lublin
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。